BIOMAT Database Logo BIOMAT Database Logo

Cutaneous Vasculitis with Gut Involvement During Secukinumab Treatment for Psoriatic Arthritis. 2020

Clara Chelli, and Jeffrey Loget, and Clélia Vanhaecke, and Anne Durlach, and Laurence Gagneux-Lemoussu, and Clothilde Soriano, and Manuelle Viguier
Department of Dermatology-Venereology, Robert-Debré Hospital, Reims, France.

UI MeSH Term Description Entries
D007079 Ileitis Inflammation of any segment of the ILEUM and the ILEOCECAL VALVE.
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009336 Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
D011695 IgA Vasculitis A systemic non-thrombocytopenic purpura caused by HYPERSENSITIVITY VASCULITIS and deposition of IGA-containing IMMUNE COMPLEXES within the blood vessels throughout the body, including those in the kidney (KIDNEY GLOMERULUS). Clinical symptoms include URTICARIA; ERYTHEMA; ARTHRITIS; GASTROINTESTINAL HEMORRHAGE; and renal involvement. Most cases are seen in children after acute upper respiratory infections. Allergic Purpura,Anaphylactoid Purpura,Henoch Purpura,Henoch-Schoenlein Purpura,Purpura Hemorrhagica,Purpura, Nonthrombocytopenic,Purpura, Schoenlein-Henoch,Rheumatoid Purpura,Schoenlein-Henoch Purpura,Vasculitis, Hemorrhagic,Henoch Schonlein Purpura,Henoch-Schonlein Purpura,Purpura, Nonthrombopenic,Purpura, Schonlein-Henoch,Hemorrhagic Vasculitis,Hemorrhagica, Purpura,Henoch Schoenlein Purpura,Henoch Schonlein Purpuras,Henoch-Schonlein Purpuras,Nonthrombocytopenic Purpura,Nonthrombopenic Purpura,Nonthrombopenic Purpuras,Purpura, Allergic,Purpura, Anaphylactoid,Purpura, Henoch,Purpura, Henoch Schonlein,Purpura, Henoch-Schoenlein,Purpura, Henoch-Schonlein,Purpura, Rheumatoid,Purpura, Schoenlein Henoch,Purpura, Schonlein Henoch,Purpuras, Henoch Schonlein,Purpuras, Henoch-Schonlein,Purpuras, Nonthrombopenic,Purpuras, Schonlein-Henoch,Schoenlein Henoch Purpura,Schonlein Purpura, Henoch,Schonlein Purpuras, Henoch,Schonlein-Henoch Purpura,Schonlein-Henoch Purpuras,Vasculitis, IgA
D002097 C-Reactive Protein A plasma protein that circulates in increased amounts during inflammation and after tissue damage. C-Reactive Protein measured by more sensitive methods often for coronary heart disease risk assessment is referred to as High Sensitivity C-Reactive Protein (hs-CRP). High Sensitivity C-Reactive Protein,hs-CRP,hsCRP,C Reactive Protein,High Sensitivity C Reactive Protein
D003092 Colitis Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER. Colitides
D003967 Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight. Diarrheas
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012867 Skin The outer covering of the body that protects it from the environment. It is composed of the DERMIS and the EPIDERMIS.

Related Publications

Clara Chelli, and Jeffrey Loget, and Clélia Vanhaecke, and Anne Durlach, and Laurence Gagneux-Lemoussu, and Clothilde Soriano, and Manuelle Viguier
Cutaneous Vasculitis During Secukinumab Treatment.
January 2020, European journal of case reports in internal medicine,
Clara Chelli, and Jeffrey Loget, and Clélia Vanhaecke, and Anne Durlach, and Laurence Gagneux-Lemoussu, and Clothilde Soriano, and Manuelle Viguier
Cutaneous leucocytoclastic vasculitis during secukinumab treatment.
December 2021, Italian journal of dermatology and venereology,
Clara Chelli, and Jeffrey Loget, and Clélia Vanhaecke, and Anne Durlach, and Laurence Gagneux-Lemoussu, and Clothilde Soriano, and Manuelle Viguier
Sarcoidosis manifesting during treatment with secukinumab for psoriatic arthritis.
February 2021, BMJ case reports,
Clara Chelli, and Jeffrey Loget, and Clélia Vanhaecke, and Anne Durlach, and Laurence Gagneux-Lemoussu, and Clothilde Soriano, and Manuelle Viguier
Secukinumab-induced IgA vasculitis in a patient with psoriatic arthritis.
September 2023, International journal of rheumatic diseases,
Clara Chelli, and Jeffrey Loget, and Clélia Vanhaecke, and Anne Durlach, and Laurence Gagneux-Lemoussu, and Clothilde Soriano, and Manuelle Viguier
Secukinumab for the treatment of psoriatic arthritis.
October 2016, Expert review of clinical immunology,
Clara Chelli, and Jeffrey Loget, and Clélia Vanhaecke, and Anne Durlach, and Laurence Gagneux-Lemoussu, and Clothilde Soriano, and Manuelle Viguier
Secukinumab: A New Treatment Option for Psoriatic Arthritis.
June 2016, Rheumatology and therapy,
Clara Chelli, and Jeffrey Loget, and Clélia Vanhaecke, and Anne Durlach, and Laurence Gagneux-Lemoussu, and Clothilde Soriano, and Manuelle Viguier
Secukinumab and psoriatic arthritis.
March 2017, Prescrire international,
Clara Chelli, and Jeffrey Loget, and Clélia Vanhaecke, and Anne Durlach, and Laurence Gagneux-Lemoussu, and Clothilde Soriano, and Manuelle Viguier
Treatment of psoriatic arthritis with secukinumab: a case series.
January 2018, The Journal of dermatological treatment,
Clara Chelli, and Jeffrey Loget, and Clélia Vanhaecke, and Anne Durlach, and Laurence Gagneux-Lemoussu, and Clothilde Soriano, and Manuelle Viguier
Treatment with secukinumab in multi-comorbid patients with psoriatic arthritis.
January 2018, The Journal of dermatological treatment,
Clara Chelli, and Jeffrey Loget, and Clélia Vanhaecke, and Anne Durlach, and Laurence Gagneux-Lemoussu, and Clothilde Soriano, and Manuelle Viguier
Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis.
December 2016, Rheumatology and therapy,
Copied contents to your clipboard!